title: Expression of markers of platelet activation and the interpatient variation in response to abciximab.
abstract: Our study concerns the biological effects of abciximab (c7E3 Fab, ReoPro), a powerful new antiplatelet drug that blocks glycoprotein (GP) IIb-IIIa complexes. Samples were examined from 6 patients with coronary artery disease who received a bolus of abciximab followed by a 10- microg/min infusion for at least 18 hours before percutaneous transluminal coronary angioplasty. Inhibition of ADP-induced PA was maximal for 4 patients but partial (79% and 53%) for 2 others during the infusion. Flow cytometry performed with monoclonal antibodies (PAC-1, AP-6, and F26) specific for the "activated" GP IIb-IIIa complex revealed large decreases in the expression of activation markers on platelets during therapy, but these decreases were less marked when inhibition of ADP-induced PA was incomplete. Residual aggregation was seen for all patients during the infusion when TRAP 14-mer peptide or thrombin was the stimulus. Unblocked GP IIb-IIIa complexes were detected on thrombin-stimulated platelets from the patients by immunoelectron microscopy performed using the monoclonal antibody AP-2. Unblocked GP IIb-IIIa complexes were also detected by flow cytometry when platelets preincubated for 1 hour in vitro with abciximab under saturating conditions were (1) incubated with TRAP 14-mer or (2) permeabilized with Triton X-100. In confirming interpatient variation in the platelet response to a standard dose of abciximab, our results also show that an uninhibited internal pool of GP IIb-IIIa complexes may mediate a residual response to strong agonists.
authors.affiliation: UMR 5533 CNRS and the Unité des Soins Intensifs, Institut Fédératif de Recherche "Coeur-Vaisseaux-Thrombose," Hôpital Cardiologique, Pessac, France.
authors.forename: C
authors.initials: C
authors.lastname: Bihour
authors.forename: C
authors.initials: C
authors.lastname: Durrieu-Jaïs
authors.forename: L
authors.initials: L
authors.lastname: Macchi
authors.forename: C
authors.initials: C
authors.lastname: Poujol
authors.forename: P
authors.initials: P
authors.lastname: Coste
authors.forename: P
authors.initials: P
authors.lastname: Besse
authors.forename: P
authors.initials: P
authors.lastname: Nurden
authors.forename: A T
authors.initials: AT
authors.lastname: Nurden
mesh_terms: D000077284:Abciximab; D000368:Aged; D000789:Angina, Unstable / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015415:Biomarkers; D001792:Blood Platelets / Q000378:metabolism; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects* / Q000502:physiology*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000378:metabolism; D011300:Preoperative Care